Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Maintenance in Metastatic Neuroendocrine Carcinoma
NCT02687958Phase 2Unknown
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- May 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in neuroendocrine carcinoma (NEC) comparing Everolimus 10mg with Observation (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT02687958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687958.